Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma

Nakchbandi, W; Müller, H; Singer, Manfred V.; Löhr, Matthias; Nakchbandi, Inaam A.

doi:10.1080/00365520600575720

Cited by 27 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nakchbandi et al [25], however, in their retrospective study of patients with pancreatic cancer, found a significant effect on survival among those taking very low dose of warfarin, thus providing recent confirmation of our own findings.…”

Section: Discussionsupporting

confidence: 83%

The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study

Fagnani

Bertolini

Catena

et al. 2009

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Infections in cancer patients after implantation of a central venous device (CVD) are not infrequent and are potentially serious. The possibility of limiting this complication with antithrombotic drugs is still debated. For this observational study, we recorded the routine management of CVD in cancer patients in 18 oncology centers in Lombardy (northern Italy), assessing the effect of antithrombotic prophylaxis on catheter-related infections. Out of 1410 patients enrolled, 451 received antithrombotic prophylaxis continuously after implantation of the central line. During a median follow-up of 30 months, 57 catheter-related infections were reported in the 1390 patients seen at least once at follow-up visits (4.1% of the whole series), giving an overall incidence of 0.10 infections per 1000 catheter days. This complication was significantly more frequent among patients with an indwelling central venous catheter, or peripherally inserted catheter, than among those with a port device, and the group not given antithrombotic prophylaxis had 0.14 infective complications/1000 CVD days compared with 0.05/1000 CVD days (odds ratio 2.4; 95% confidence interval 1.7-5.0) for those treated. Antithrombotic prophylaxis protected against infections at the catheter exit site and track but not against systemic infections. Confirming earlier evidence, this study found a reduction in catheter-related infections in patients given antithrombotic prophylaxis. However, this reduction, reflecting local infections, seems unlikely to be one of the mechanisms explaining the lower mortality among our patients treated with anticoagulants.

show abstract

Section: Discussionsupporting

confidence: 83%

The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study

Fagnani

Bertolini

Catena

et al. 2009

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…Indeed, in a large population-based study, longterm treatment with vitamin K antagonists was associated with reduced risk for cancer development, especially prostate cancer (37 ). Substantiating this, Nakchbandi et al reported that low doses of the vitamin K antagonist warfarin increased survival of patients with pancreatic carcinoma (38 ). However, it is thus far unclear whether these effects depend solely on flTF-mediated processes.…”

Section: Therapeutic Implications Of Targeting Tfmentioning

confidence: 97%

Tissue Factor: A Conventional or Alternative Target in Cancer Therapy

2016

View full text Add to dashboard Cite

BACKGROUND:Tissue factor (TF) is an evolutionary conserved glycoprotein that plays an important role in the pathogenesis of cancer. TF is expressed in 2 naturally occurring protein isoforms, membrane-bound full-length (fl)TF and soluble alternatively spliced (as)TF. Both isoforms have been shown to affect a variety of pathophysiologically relevant functions, such as tumor-associated angiogenesis, thrombogenicity, tumor growth, and metastasis. Therefore, targeting TF either by direct inhibition or indirectly, i.e., on a posttranscriptional level, offers a novel therapeutic option for cancer treatment.CONTENT: In this review we summarize the latest findings regarding the role of TF and its isoforms in cancer biology. Moreover, we briefly depict and discuss the therapeutic potential of direct and/or indirect inhibition of TF activity and expression for the treatment of cancer.

show abstract

“…Three studies also included adjuncts to chemotherapy: warfarin, angiotensin-II, and degradable starch microspheres. [26, 28, 37]…”

Section: Methodsmentioning

confidence: 99%

Expanding Surgical Treatment of Pancreatic Cancer

et al. 2012

View full text Add to dashboard Cite

Objectives Pancreatic cancer is a lethal disease that offers little chance of long-term survival for patients with unresectable tumors. Surgery remains the most effective means of attaining prolonged survival, yet its role remains limited. Regional chemotherapy has been described for patients with pancreatic cancer, including reports of objective tumor regression allowing for tumor resection in previously unresectable cases, however comprehensive data have not been reviewed to date. Methods A review of the literature from 1995 to 2010 was performed to analyze the results of regional chemotherapy administered to patients with advanced pancreatic cancer. Reports of individual cases, post-operative regional therapy and treatment of mixed tumor types were excluded. Results Twenty-one reports of 895 total patients with pancreatic cancer were reviewed. Greater than 95% of patients had stage III or IV adenocarcinoma. Objective response rates ranged from nil to 58%, with associated median survivals of 4 to 22 months. Low grade gastrointestinal and hematologic toxicities were not uncommon. Conclusions Regional chemotherapy can be administered safely to patients with pancreatic cancer, but with unclear benefit. Advanced pancreatic tumors converted to resectable status by the use of regional chemotherapy may improve patient survival.

show abstract

Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma

Cited by 27 publications

References 33 publications

The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study

The impact of antithrombotic prophylaxis on infectious complications in cancer patients with central venous catheters: an observational study

Tissue Factor: A Conventional or Alternative Target in Cancer Therapy

Expanding Surgical Treatment of Pancreatic Cancer

Contact Info

Product

Resources

About